Buyback yield (TTM)
1.23%
Shareholder yield (TTM)
1.84%
5Y share count change
1.3%
Buyback spend (TTM)
$100M
Cumulative buybacks
$1.01B
Key takeaways
- Bio-Techne (TECH) repurchased about $100M of stock over the trailing twelve months.
- Diluted share count is up 1.3% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
- TTM buyback ÷ stock-based-comp ratio of 2.46× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +40.6% per year over the latest 5-year window.
- TTM repurchases used about 46% of free cash flow remaining after dividends.
Dividend & buyback yield over time for Bio-Techne (TECH)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Bio-Techne (TECH)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Bio-Techne (TECH)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Bio-Techne (TECH)
Latest: $276M
Overview
Bio-Techne (TECH) most recent annual buyback spend stands at $276M (2025) – surged 244.5% year-over-year.
Over 2020–2025 (5 years), Bio-Techne buyback spend expanded at a +40.6% compound annual rate, sustaining 2 straight years of year-over-year growth.
$276M stands as the all-time-high annual buyback spend, posted in 2025, against a low of $0.00 during 1991.
Bio-Techne Buyback Spend 2025: $276M
In 2025, Bio-Techne reported buyback spend of $276M, surged 244.5% from 2024. This figure represents the highest annual value in the available history.
Bio-Techne Buyback Spend 2024: $80M
Bio-Techne buyback spend in 2024 was $80M, surged 309.2% from 2023.
Bio-Techne Buyback Spend 2023: $19.6M
2023's buyback spend for Bio-Techne came in at $19.6M, plunged 87.8% below 2022.
Bio-Techne Buyback Spend 2022: $161M
Bio-Techne posted buyback spend of $161M in 2022, surged 272.8% from 2021.
Bio-Techne Buyback Spend 2021: $43.2M
Bio-Techne buyback spend in 2021 was $43.2M.
See more financial history for Bio-Techne (TECH).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $276M | $40.8M | $235M | 3.46% | 160M | -0.7% | |
| 2024 | $80M | $38M | $42M | 0.71% | 161M | -0.7% | |
| 2023 | $19.6M | $39.2M | -$19.7M | 0.15% | 162M | -1.4% | |
| 2022 | $161M | $42.2M | $119M | 1.18% | 164M | +1.3% | |
| 2021 | $43.2M | $49M | -$5.8M | 0.25% | 162M | +2.7% | |
| 2020 | $50.1M | $32.4M | $17.7M | 0.50% | 158M | +1.3% | |
| 2019 | $15.4M | $32.3M | -$16.9M | 0.19% | 156M | +2.2% | |
| 2018 | $0.00 | $28.2M | -$28.2M | — | 152M | +1.5% | |
| 2017 | $0.00 | $14.6M | -$14.6M | — | 150M | +0.5% | |
| 2016 | $0.00 | $9.43M | -$9.43M | — | 149M | +0.3% | |
| 2015 | $0.00 | $5.96M | -$5.96M | — | 149M | +0.6% | |
| 2014 | $0.00 | $3.52M | -$3.52M | — | 148M | +0.3% | |
| 2013 | $2.39M | $1.86M | $530K | 0.09% | 148M | -0.3% | |
| 2012 | $24.5M | $1.64M | $22.9M | 0.90% | 148M | -0.4% | |
| 2011 | $2.23M | $1.14M | $1.1M | 0.07% | 149M | -0.5% | |
| 2010 | $15.6M | $1.14M | $14.4M | 0.73% | 149M | -1.5% | |
| 2009 | $92.3M | $1.48M | $90.8M | 3.88% | 152M | -3.4% | |
| 2008 | $60.2M | $0.00 | $60.2M | 2.01% | 157M | -0.7% | |
| 2007 | $1.22M | $0.00 | $1.22M | 0.05% | 158M | -0.2% | |
| 2006 | $27.3M | $0.00 | $27.3M | 1.36% | 158M | -3.2% | |
| 2005 | $104M | $0.00 | $104M | 5.84% | 164M | -1.9% | |
| 2004 | $0.00 | $0.00 | $0.00 | — | 167M | -0.8% | |
| 2003 | $23.7M | $0.00 | $23.7M | 1.90% | 168M | -1.2% | |
| 2002 | $746K | $0.00 | $746K | 0.06% | 170M | -0.3% | |
| 2001 | $1.16M | $0.00 | $1.16M | 0.09% | 171M | +1.1% | |
| 2000 | $0.00 | $0.00 | $0.00 | — | 169M | +2.0% | |
| 1999 | $3.9M | $0.00 | $3.9M | — | 165M | +5.5% | |
| 1998 | $300K | $0.00 | $300K | — | 157M | +0.7% | |
| 1997 | $3.2M | $0.00 | $3.2M | — | 156M | +0.1% | |
| 1996 | $700K | $0.00 | $700K | — | 156M | — | |
| 1995 | $600K | $0.00 | $600K | — | — | — | |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1992 | $200K | $0.00 | $200K | — | — | — | |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1990 | $200K | $0.00 | $200K | — | — | — |
- 2025$276M
- 2024$80M
- 2023$19.6M
- 2022$161M
- 2021$43.2M
- 2020$50.1M
- 2019$15.4M
- 2018$0.00
- 2017$0.00
- 2016$0.00
- 2015$0.00
- 2014$0.00
- 2013$2.39M
- 2012$24.5M
- 2011$2.23M
- 2010$15.6M
- 2009$92.3M
- 2008$60.2M
- 2007$1.22M
- 2006$27.3M
- 2005$104M
- 2004$0.00
- 2003$23.7M
- 2002$746K
- 2001$1.16M
- 2000$0.00
- 1999$3.9M
- 1998$300K
- 1997$3.2M
- 1996$700K
- 1995$600K
- 1994$0.00
- 1993$0.00
- 1992$200K
- 1991$0.00
- 1990$200K
Buybacks vs stock-based compensation for Bio-Techne (TECH)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 2.46×.
Buybacks vs dividends (share of cash returned) for Bio-Techne (TECH)
How Bio-Techne splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Bio-Techne, ranked by their latest buyback spend.
| $5.95B | |
| $5.55B | |
| $5.08B | |
| $4.11B | |
| $3B | |
| $980M | |
| $216M | |
| $0.00 |
- $5.95B
- $5.55B
- $5.08B
- $4.11B
- $980M
- $216M
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $220M (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks1.23% TTM
- Dividend Profile0.44% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History3 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.